Physician

Stephen Henry Wrzesinski, M.D., PHD

According to 2025 Medicare claims, Stephen Wrzesinski, M.D., PHD (NPI: 1780856971) practices medical oncology in the Albany-Schenectady-Troy, NY market, with the plurality of this provider's patient population coming from Albany, NY. This provider's primary affiliated billing organization is NEW YORK ONCOLOGY HEMATOLOGY, P.C. (NPI: 1609863448; TIN: 141799724) and primary practice location at 12206-5104. Wrzesinski is affiliated with the Bassett Accountable Care Partners, LLC (ACO ID: A2612) and Trinity Health Integrated Care (ACO ID: A3454), participating under the MSSP model.

Wrzesinski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 411 traditional Medicare patients, billed 78,184 HCPCS/CPT codes, and received $2,205,114 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 783 prescription claims across 108 beneficiaries totaling $1,259,723 in drug costs, led by Erivedge (Vismodegib). 2018 DME data shows 122 claims. Open Payments data shows 68 records totaling $68,381. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $41,770 to $2,205,114. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,457 to $1,190.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	197	694	$41,770
2016	180	718	$40,814
2017	196	699	$42,671
2018	251	821	$54,530
2019	367	34,601	$790,354
2020	364	60,344	$1,465,765
2021	345	51,998	$1,165,364
2022	344	63,468	$1,455,507
2023	378	73,718	$1,840,277
2024	411	78,184	$2,205,114

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	120	859	$942,646
2016	149	1,106	$1,273,452
2017	145	834	$1,046,859
2018	161	970	$950,828
2019	120	606	$768,551
2020	68	455	$1,092,944
2021	79	587	$1,321,724
2022	97	648	$1,413,205
2023	117	844	$1,435,564
2024	108	783	$1,259,723

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	198	$30,723
2016	N/R	224	$8,675
2017	N/R	11	$92
2018	N/R	122	$9,156
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	189	525	$91
84443	Blood test, thyroid stimulating hormone (tsh)	86	284	$16
80053	Blood test, comprehensive group of blood chemicals	249	685	$10
36415	Insertion of needle into vein for collection of blood sample	236	631	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	252	675	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Erivedge	Vismodegib	23	648	$281,229
Tagrisso	Osimertinib Mesylate	22	660	$273,516
Alecensa	Alectinib Hcl	13	390	$232,253
Bexarotene	Bexarotene	13	390	$71,885
Eliquis	Apixaban	68	2,400	$45,937

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$361	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	64	$68,020	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Stephen Henry Wrzesinski, M.D., PHD?

Tedicare shows public-source Medicare data for Stephen Henry Wrzesinski, M.D., PHD (NPI 1780856971), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stephen Henry Wrzesinski, M.D., PHD have ACO affiliation data?

Stephen Henry Wrzesinski, M.D., PHD is shown with ACO affiliation data for Bassett Accountable Care Partners, LLC (MSSP, ACO ID A2612) and Trinity Health Integrated Care (MSSP, ACO ID A3454).

What billing organization is linked to Stephen Henry Wrzesinski, M.D., PHD?

Stephen Henry Wrzesinski, M.D., PHD is linked to NEW YORK ONCOLOGY HEMATOLOGY, P.C. (billing NPI 1609863448) in the available physician profile data.

Does Stephen Henry Wrzesinski, M.D., PHD have Open Payments data?

Stephen Henry Wrzesinski, M.D., PHD has 68 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.